Welcome to the e-CCO Library!

P531: Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region
Year: 2022
Source: ECCO'22
Authors: Kumar, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Sahu, P.(1);Goyal, S.(1);Madhu, D.(1);Jain, S.(1);Ranjan, M.K.(1);Mundhra, S.(1);Golla, R.(1);Singh, M.(1);Virmani, S.(1);Gupta, A.(1);Yadav, N.(1);Kalaivani, M.(1);Sharma , R.(1);Das, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:56 PM
P531: Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agents
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Fragaki*, G. Paspatis, K. Karmiris

Created: Thursday, 21 February 2019, 9:14 AM
P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. EMONT1, C. Gay2, A.L. Parmentier3, S. Koch4, S. Ambregna5, G. Claudé5, P. Sage5, P. Zhong4, C. Briot5, L. Vuitton4

Created: Thursday, 30 January 2020, 10:12 AM
P532: 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Song, J.H.(1);Hong, S.N.(2)*;Kim, E.R.(3);Kim, J.E.(3);Chang, D.K.(3);Kim, Y.H.(3);
Created: Friday, 14 July 2023, 11:05 AM
P532: Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kolar M.*1, Duricova D.1,2, Bortlik M.1,3, Hruba V.1, Machkova N.1, Mitrova K.1,4, Lukas M.1, Malickova K.5, Lukas M.1,5

Created: Wednesday, 20 February 2019, 10:36 AM
P532: Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic
Year: 2021
Source: ECCO'21 Virtual
Authors: Guo, H.(1);Tang, J.(1);Huang, Z.(1);Li, B.(1);Yang, Q.(1);Chao, K.(1);Gao, X.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P532: Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agents
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Rutka*, K. Szántó, R. Bor, A. Bálint, A. Fábián, A. Milassin, Z. Szepes, K. Farkas, T. Molnar

Created: Thursday, 21 February 2019, 9:14 AM
P532: Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels
Year: 2022
Source: ECCO'22
Authors: Botto, I.(1);Coelho Rodrigues, I.(1);Serrazina, J.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P532: Safety and efficacy of endoscopic dilation of small bowel Crohn’s disease strictures by balloon-assisted enteroscopy: pooled analysis of individual data from 210 patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Bettenworth*1, A. Bokemeyer1, L. Kou2, R. Lopez2, B. P. Halloran3, M. Reeson3, S. Hosomi4, M. Kishi5, F. Hirai5, N. Ohmiya6, F. Rieder7,8

Created: Friday, 22 February 2019, 9:41 AM
P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Angriman, G. Bordignon, E. Sciuto, O. Zini, N. Bortoli, M. Gruppo, R. Bardini, C. Ruffolo, M. Scarpa

Created: Thursday, 30 January 2020, 10:12 AM
P533: Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Year: 2021
Source: ECCO'21 Virtual
Authors: Calvo Moya, M.I.(1);Omella Usieto, I.(2);El Hajra Martinez, I.(2);Santos Perez, E.(2);Gonzalez Lama, Y.(1);Ruiz Antoran, B.(3);Menchen Viso, B.(4);Matallana Royo, V.(1);Gonzalez Partida, I.(1);De Lucas Tellez de Meneses, R.(1);Bella del Castillo, P.(1);Gonzalez Rodriguez, M.(1);Vera Mendoza, M.I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P533: Anaemia and iron deficiency in gastroenterology: a Scandinavian prospective, observational study of iron isomaltoside in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Frigstad S.O.*1,2,3, Hammarlund P.4, Bonderup O.5, Rannem T.6, Haaber A.7, Fallingborg J.8, Blom H.9, Bajor A.10,11, Hellström P.M.12

Created: Wednesday, 20 February 2019, 10:36 AM
P533: Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study
Year: 2018
Source: ECCO '18 Vienna
Authors:

W.J. Sandborn1*, B. Feagan2, J.D. Lewis3, S. Danese4, W. Reinisch5, D.T. Rubin6, W. Zhou7, F. Cataldi7, Q. Zhou7, S. Goteti7, A.P. Lacerda7

Created: Thursday, 21 February 2019, 9:14 AM
P533: Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
Year: 2022
Source: ECCO'22
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Sabino, J.(2,3);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P533: Relation between TL1A expression in intestinal mucosa, and endoscopic severity and clinical course in ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Shimodaira, Y.(1)*;Yoshida, T.(1);Watanabe, K.(1);Takahashi, S.(1);Fukuda, S.(1);Koizumi, S.(1);Matsuhashi, T.(1);Iijima, K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P533: Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Heron*1,2, T. Bessissow1, A. Bitton1, P. Lakatos1, E. Seidman1, A. Jain3, R. Battat1,4, P. Germain1, C. Lemieux1, W. Afif1

Created: Friday, 22 February 2019, 9:41 AM
P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Popov1,2, E. Hartung1, L. Hill1,3, U. Chauhan4, N. Pai1,5, McMaster Paediatric FMT Research Program

Created: Thursday, 30 January 2020, 10:12 AM
P534: Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cohen, S.(1);Olbjorn, C.(2);Kolho, K.L.(3); Aloi, M.(4);Musto, F.(4);de-Carpi, J.M.(5);Lozano-Ruf, A.(5);Yogev, D.(6);Matar, M.(7);Scarallo, L.(8); Bramuzzo, M.(9); de Ridder, L.(10); Kang, B.(11);Norden, C.(12);Wilson, D.C.(13);Tzivinikos, C.(14); Turner, D.(6);Yerushalmy-Feler, A.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P534: Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
Year: 2022
Source: ECCO'22
Authors: Gros , B.(1);Soto Escribano , P.(1);Marín Pedrosa , S.(1);Medina Medina , R.(2);Benítez , J.M.(1);Iglesias-Flores , E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P534: IBD-related malignancies observed in 2015–2018: 4 years’ results from the prospective nationwide Hungarian registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Milassin*1, M. Rutka1, K. Farkas1, A. Bálint1, R. Bor1, A. Fábián1, Z. Szepes1, T. Szamosi2, K. Szántó1, P. Miheller3, Z. Barta4, J. Banai2, Á. Kovács5, Á. Salamon6, L. Lakatos7, L. Lakner7, K. Palatka8, M. Papp9, E. Schafer2, J. Novák10, Z. Erdélyi11, Z. Kürti12, P. L. Lakatos12, P. Sarlós13, N. Szigeti14, G. Veres9, A. Zaránd16, A. Gelley17, Á. Vincze18, F. Nagy1, T. Molnár1

Created: Friday, 22 February 2019, 9:41 AM